BACKGROUND Recent studies have reported CD10 expression in myoepithelial cells (MEC) of the breast, supporting its use as a marker to help distinguish invasive breast carcinoma (IC) from ductal carcinoma in situ (DCIS). AIM To compare the effectiveness of CD10 with smooth muscle myosin heavy chain (SMMHC) in the detection of MEC in benign and malignant breast lesions. METHODS Histological m...

Aim: CD10 is a cell surface metalloprotease that inactivates various bioactive neuropeptides. CD10 has been suggested as a useful prognostic marker for urothelial carcinoma, but there are only a few studies of CD10 in urothelial tumors and they have shown varying results. The aims of this study were to investigate the expression of CD10 in urothelial bladder carcinomas and to clarify its associ...

BACKGROUND AND OBJECTIVES B-cell chronic lymphocytic leukemia (B-CLL) is an accumulating disease of slowly proliferating cells. CD10 is not normally expressed on the surface of B-CLL cells. The aim of this study was to ascertain whether B-CLL cells, induced into apoptosis, expressed surface CD10, since a correlation between apoptosis and CD10 expression has been demonstrated. DESIGN AND METHO...

BACKGROUND Requirements for human B lymphopoiesis are still poorly understood, and that has hampered investigation of differentiation events. For example, there are few cell surface antigens that can be used as milestones of lineage progression. The CD10 ectoenzyme is one such marker and has been used to define CLP, but we found substantial tissue specific variations in CD10 levels, and there w...

Background & Objectives:  CD10 is a cell surface enzyme with metalloendopeptidase activity, also known as Common Acute Lymphoblastic Leukaemia Antigen, which mainly serves as a marker for acute lymphoblastic leukemia (ALL). To date and to the best of our knowledge, only few comparative immunohistochemical studies have assessed CD10 expression in cutaneous epithelial neoplasms. Our goal was to d...

BACKGROUND CD10 is a transmembrane metallo-endopeptidase that cleaves and inactivates a variety of peptide growth factors. Loss of CD10 expression is a common, early event in human prostate cancer; however, CD10 positive cancer cells frequently appear in lymph node metastasis. We hypothesize that prostate tumors expressing high levels of CD10 have a more aggressive biology with an early propens...

BACKGROUND CD10 and CD34 have been detected in both epithelial and mesenchymal components of anagen human hair follicles. OBJECTIVES To analyse the expression of CD10 and CD34 in human hair follicle development as well as in different phases of the hair cycle. METHODS Fetal and adult hair follicles at different stages of the hair cycle were examined by immunohistochemistry for CD10 and CD34...

PURPOSE There is growing evidence that interaction between stromal and tumor cells is pivotal in breast cancer progression and response to therapy. Based on earlier research suggesting that during breast cancer progression, striking changes occur in CD10(+) stromal cells, we aimed to better characterize this cell population and its clinical relevance. EXPERIMENTAL DESIGN We developed a CD10(+...

Introduction: Burkitt lymphoma (BL) is a rare but highly aggressive B-cell non-Hodgkin lymphoma. BL exhibits characteristic immunophenotype that positive for pan-B cell markers and CD10. The genetic hallmark of the translocation MYC oncogene under regulation an immunoglobulin (IG) heavy or light chain enhancer, resulting in protein overexpression. Notably, by itself not sufficient oncogenesis v...

CD10 is a cell surface zinc-dependent endopeptidase, which degrades many bioactive peptides. CD10 expression in tumour stroma is associated with biological aggressiveness of many epithelial malignancies. To date, only one study has correlated with expression of CD10 with well-known prognostic markers of breast, that is, ER, PR, HER2-neu, and tumour grade; however, its correlation with ki67 is s...